MetALD: Genetic Factors and Clinical Outcomes

Abstract

Metabolic and alcohol-related liver disease (MetALD) is a subcategory of steatotic liver disease (SLD) characterized by the coexistence of cardiometabolic risk factors and elevated alcohol intake. The global prevalence of MetALD is estimated to be 2 to 5%, but this is likely underestimated due to self-reporting biases. In real-world settings, fluctuations in alcohol intake mean that many patients with SLD may be classified as having MetALD at some point during their disease. Although MetALD is relatively common, only a minority of patients with the disorder progress to advanced chronic liver disease. Genetic factors modulate disease initiation and progression, with risk variants in PNPLA3, HSD17B13, and TM6SF2 being particularly relevant. Polygenic risk scores incorporating these and other variants have demonstrated a potential for identifying at-risk individuals. This review comprehensively examines MetALD, covering its natural history, genetic underpinnings, clinical outcomes, the predictive potential of genetic risk scores, and future therapeutic avenues involving gene silencing.

Keywords

cirrhosis - polygenic risk score - hepatocellular carcinoma - fatty liver - nonalcoholic steatohepatitis

Publikationsverlauf

Accepted Manuscript online:
09. Juni 2025

Artikel online veröffentlicht:
27. Juni 2025

• References

• 1 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
• 2 Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet 2024; 404 (10464): 1761-1778
• 3 Karlsen TH, Sheron N, Zelber-Sagi S. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022; 399 (10319): 61-116
• 4 Kim D, Konyn P, Cholankeril G, Wong RJ, Younossi ZM, Ahmed A. Hepatocellular Carcinoma Research Committee for Chronic Liver Disease Foundation. Decline in annual mortality of hepatitis C virus-related hepatocellular carcinoma in the United States, from 2009 to 2018. Gastroenterology 2020; 159 (04) 1558-1560.e2
• 5 Torp N, Israelsen M, Krag A. The steatotic liver disease burden paradox: unravelling the key role of alcohol. Nat Rev Gastroenterol Hepatol 2025; 22 (04) 281-292
• 6 Younossi Z, Anstee QM, Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15 (01) 11-20
• 7 Rinella ME, Lazarus JV, Ratziu V. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023
• 8 Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther 2024; 59 (10) 1271-1281
• 9 Xiao Y, Xu S, Hu W. et al. Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases. Ann Hepatol 2025; 30 (01) 101750
• 10 Zeng H, Fang L, Yang Z. et al. Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study. MedComm 2025; 6 (02) e70087
• 11 Tamaki N, Kimura T, Wakabayashi SI. et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther 2024; 60 (01) 61-69
• 12 Lee HH, Lee HA, Kim EJ. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 2024; 73 (03) 533-540
• 13 Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine 2023; 65: 102292
• 14 Yun B, Park H, Ahn SH, Oh J, Kim BK, Yoon JH. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study. Am J Gastroenterol 2025; 120 (02) 410-419
• 15 Kim GA, Jeong S, Jang H, Lee DH, Joo SK, Kim W. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a Korean nationwide study. Liver Cancer 2023; 13 (04) 426-437
• 16 Park Y, Jung J, Han S, Kim GA. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: a nationwide cohort study. Aliment Pharmacol Ther 2024; 60 (11–12): 1599-1608
• 17 Lee CM, Yoon EL, Kim M. et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology 2024; 79 (06) 1393-1400
• 18 Männistö V, Salomaa V, Jula A. et al. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population. JHEP Rep Innov Hepatol 2024; 6 (10) 101172
• 19 Younossi ZM, de Avila L, Racila A. et al. Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology 2025
• 20 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 2024; 79 (03) 666-673
• 21 Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep Innov Hepatol 2024; 6 (10) 101127
• 22 Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 2023; 43 (11) 2425-2433
• 23 Israelsen M, Thorhauge KH, Andersen P. et al. Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments. Clin Gastroenterol Hepatol 2025 S1542-3565(25)00243-5
• 24 Nasr P, Wester A, Ekstedt M. et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol 2024; 22 (05) 1048-1057.e2
• 25 Staufer K, Huber-Schönauer U, Strebinger G. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol 2022; 77 (04) 918-930
• 26 Scholten K, Twohig P, Samson K. et al. You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients. Dig Liver Dis 2024; 56 (07) 1215-1219
• 27 Krag A, Torp N, Younossi ZM, Israelsen M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol Hepatol 2025; 10 (04) 282-284
• 28 Sultanik P, Lherault G, Bouzbib C. et al. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: a single-centre prospective study. Aliment Pharmacol Ther 2024; 60 (06) 796-810
• 29 Pessione F, Ramond MJ, Peters L. et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23 (01) 45-53
• 30 Hansen ED, Torp N, Johansen S. et al; GALAXY and MicrobLiver consortia. Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake. JHEP Rep Innov Hepatol 2024; 7 (01) 101200
• 31 Lassailly G, Caiazzo R, Ntandja-Wandji LC. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159 (04) 1290-1301.e5
• 32 Ghouse J, Sveinbjörnsson G, Vujkovic M. et al; DBDS Genomic Consortium, Regeneron Genetics Center, Geisinger-Regeneron DiscovEHR Collaboration, VA Million Veteran Program, Estonian Biobank Research Team. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat Genet 2024; 56 (05) 827-837
• 33 Israelsen M, Torp N, Johansen S, Thiele M, Krag A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol 2023; 8 (10) 866-868
• 34 Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB. et al; DBDS Genomic consortium. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022; 54 (11) 1652-1663
• 35 Abul-Husn NS, Cheng X, Li AH. et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018; 378 (12) 1096-1106
• 36 Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol 2023; 78 (01) 191-206
• 37 Kozlitina J. Genetic risk factors and disease modifiers of nonalcoholic steatohepatitis. Gastroenterol Clin North Am 2020; 49 (01) 25-44
• 38 Trépo E, Caruso S, Yang J. et al; GENTHEP Consortium. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncol 2022; 23 (01) 161-171
• 39 Romeo S, Kozlitina J, Xing C. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
• 40 Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol 2016; 65 (02) 399-412
• 41 Smagris E, BasuRay S, Li J. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61 (01) 108-118
• 42 Kim HS, Xiao X, Byun J. et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw Open 2022; 5 (10) e2234221
• 43 Unalp-Arida A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. Hepatology 2020; 71 (03) 820-834
• 44 Gellert-Kristensen H, Tybjaerg-Hansen A, Nordestgaard BG. et al. Genetic risk of fatty liver disease and mortality in the general population: a Mendelian randomization study. Liver Int 2023; 43 (09) 1955-1965
• 45 Stender S, Loomba R. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 2020; 71 (03) 777-779
• 46 Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte 2019; 8 (01) 201-208
• 47 Wang Y, Hong S, Hudson H. et al. PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis. J Hepatol 2025; 82 (05) 871-881
• 48 Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016; 291 (20) 10659-10676
• 49 Luo F, Smagris E, Martin SA. et al. Hepatic TM6SF2 is required for lipidation of VLDL in a pre-Golgi compartment in mice and rats. Cell Mol Gastroenterol Hepatol 2022; 13 (03) 879-899
• 50 Holmen OL, Zhang H, Fan Y. et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46 (04) 345-351
• 51 Dongiovanni P, Petta S, Maglio C. et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61 (02) 506-514
• 52 Horiguchi Y, Araki M, Motojima K. 17beta-hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein. Biochem Biophys Res Commun 2008; 370 (02) 235-238
• 53 Stender S, Romeo S. HSD17B13 as a promising therapeutic target against chronic liver disease. Liver Int 2020; 40 (04) 756-757
• 54 Kozlitina J, Stender S, Hobbs HH, Cohen JC. HSD17B13 and chronic liver disease in Blacks and Hispanics. N Engl J Med 2018; 379 (19) 1876-1877
• 55 Buch S, Stickel F, Trépo E. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015; 47 (12) 1443-1448
• 56 Emdin CA, Haas ME, Khera AV. et al. Correction: a missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease. PLoS Genet 2021; 17 (04) e1009503
• 57 Jamialahmadi O, Mancina RM, Ciociola E. et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology 2021; 160 (05) 1634-1646.e7
• 58 Teo K, Abeysekera KWM, Adams L. et al; EU-PNAFLD Investigators, GOLD Consortium. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol 2021; 74 (01) 20-30
• 59 Verweij N, Haas ME, Nielsen JB. et al. Germline mutations in CIDEB and protection against liver disease. N Engl J Med 2022; 387 (04) 332-344
• 60 Li D, Zhao H, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet 2012; 131 (05) 725-737
• 61 Vilar-Gomez E, Sookoian S, Pirola CJ. et al. ADH1B∗2 is associated with reduced severity of nonalcoholic fatty liver disease in adults, independent of alcohol consumption. Gastroenterology 2020; 159 (03) 929-943
• 62 Forman D, Yang M, Chien R. et al. ALDH2 deficiency and alcohol intake in the United States: opportunity for precision cancer prevention. Cancer Epidemiol Biomarkers Prev 2025; 34 (05) 744-753
• 63 Yokoyama A, Muramatsu T, Ohmori T. et al. Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 1998; 19 (08) 1383-1387
• 64 European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol 2022; 77 (02) 479-502
• 65 Hamesch K, Mandorfer M, Pereira VM. et al; European Alpha1-Liver Study Group. Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation. Gastroenterology 2019; 157 (03) 705-719.e18
• 66 Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol 2022; 76 (04) 946-958
• 67 Tuschl K, Clayton PT, Gospe Jr SM. et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 2012; 90 (03) 457-466
• 68 Quadri M, Federico A, Zhao T. et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 2012; 90 (03) 467-477
• 69 Ward LD, Tu HC, Quenneville CB. et al; Regeneron Genetics Center, Geisinger-Regeneron DiscovEHR Collaboration. GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms. Nat Commun 2021; 12 (01) 4571
• 70 Seidelin AS, Nordestgaard BG, Tybjærg-Hansen A, Yaghootkar H, Stender S. A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. Hepatol Int 2022; 16 (03) 702-711
• 71 Israelsen M, Torp N, Johansen S. et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol 2024; 9 (03) 218-228
• 72 Oh JH, Ahn SB, Cho S, Nah EH, Yoon EL, Jun DW. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol 2024; 81 (05) 772-780
• 73 Díaz LA, Tavaglione F, Mittal N. et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol Commun 2025; 9 (06) e0718
• 74 Rehm J, Gmel Sr GE, Gmel G. et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction 2017; 112 (06) 968-1001
• 75 Wood AM, Kaptoge S, Butterworth AS. et al; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018; 391 (10129): 1513-1523
• 76 Aboona MB, Danpanichkul P, Chen VL. et al. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. J Gastroenterol Hepatol 2024; 39 (11) 2456-2463
• 77 Kimura T, Tamaki N, Wakabayashi SI. et al. Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol 2025 S1542-3565(25)00074-6
• 78 Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int 2024; 44 (08) 1762-1767
• 79 Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (01) 108-111
• 80 Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340: c1240
• 81 Pose E, Pera G, Torán P. et al. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study. Liver Int 2021; 41 (07) 1556-1564
• 82 Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018; 67 (06) 2141-2149
• 83 Åberg F, Puukka P, Salomaa V. et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol 2020; 18 (04) 995-997.e2
• 84 Sahlman P, Nissinen M, Puukka P. et al. Genetic and lifestyle risk factors for advanced liver disease among men and women. J Gastroenterol Hepatol 2020; 35 (02) 291-298
• 85 Israelsen M, Juel HB, Detlefsen S. et al; GALAXY and MicrobLiver consortiak. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin Gastroenterol Hepatol 2022; 20 (08) 1784-1794.e9
• 86 Whitfield JB, Schwantes-An TH, Darlay R. et al; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol 2022; 76 (02) 275-282
• 87 Galvanin C, Buch S, Nahon P, Trépo E. PNPLA3 in alcohol-related liver disease. Liver Int 2025; 45 (01) e16211
• 88 Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol 2020; 72 (06) 1196-1209
• 89 De Vincentis A, Tavaglione F, Jamialahmadi O. et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 2022; 20 (03) 658-673
• 90 Bianco C, Jamialahmadi O, Pelusi S. et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 2021; 74 (04) 775-782
• 91 Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020; 72 (03) 845-856
• 92 Schwantes-An TH, Whitfield JB, Aithal GP. et al; GenomALC Consortium. A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry. Hepatol Commun 2024; 8 (06) e0431
• 93 Nahon P, Bamba-Funck J, Layese R. et al; ANRS CO12 CirVir and CIRRAL groups. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. J Hepatol 2023; 78 (03) 584-595
• 94 Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 2022; 77 (02) 365-376
• 95 Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab 2020; 31 (01) 35-45
• 96 Strnad P, Schrader C, Brunetti-Pierri N. A gene silencing-based approach to tackle fatty liver disease. Mol Ther Methods Clin Dev 2024; 32 (01) 101198
• 97 Mak LY, Gane E, Schwabe C. et al. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol 2023; 78 (04) 684-692
• 98 Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023; 20 (12) 764-783
• 99 Lemmer P, Manka P, Best J. et al. Effects of moderate alcohol consumption in non-alcoholic fatty liver disease. J Clin Med 2022; 11 (03) 890
• 100 Israelsen M, Kim M, Suvitaival T. et al; MicrobLiver Consortium. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep Innov Hepatol 2021; 3 (05) 100325
• 101 Lanng AR, Gasbjerg LS, Bergmann NC. et al. Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocr Connect 2019; 8 (10) 1372-1382
• 102 Arab JP, Diaz LA, Rehm J. et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol 2024; 82 (04) 744-756
• 103 Lee BP, Molina J, Kim S, Dodge JL, Terrault NA. Association of alcohol and incremental cardiometabolic risk factors with liver disease: a national cross-sectional study. Clin Gastroenterol Hepatol 2025 S1542-3565(25)00081-3
• 104 Marti-Aguado D, Calleja JL, Vilar-Gomez E. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol 2024; 81 (06) 930-940
• 105 Israelsen M, Rungratanawanich W, Thiele M, Liangpunsakul S. Non-invasive tests for alcohol-associated liver disease. Hepatology 2024; 80 (06) 1390-1407
• 106 Tavaglione F, Amangurbanova M, Yang AH. et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study. Aliment Pharmacol Ther 2025; 61 (06) 1043-1054
• 107 Krag A, Torp N, Israelsen M. Letter to the editor: alcohol a confounding factor in the assessment of resmetirom therapy. Hepatology 2025; 81 (06) E162-E163
• 108 Harrison SA, Bedossa P, Guy CD. et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024; 390 (06) 497-509
• 109 Lee BP, Witkiewitz K, Mellinger J. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nat Rev Gastroenterol Hepatol 2024; 21 (09) 626-645
• 110 Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism 2024; 153: 155800
• 111 Kwak M, Kim HS, Jiang ZG. et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology 2024
• 112 Israelsen M, Madsen BS, Torp N. et al; GALAXY, MicrobLiver Consortia. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8 (06) 523-532
• 113 Åberg F, Puukka P, Salomaa V. et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology 2020; 71 (03) 835-848